Hemophagocytic lymphohistiocytosis and primary immune deficiency disorders

Clinical Immunology

Volumn 155, Issue 1, 2014, Pages 118-125

  Faitelson, Yoram ^a   Grunebaum, Eyal ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Deficiency; Hemophagocytic; ; Immune; ; Lymphohistiocytosis; ; Primary;

Indexed keywords

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BIOGENESIS; CYTOTOXICITY; DISEASE ASSOCIATION; GENETIC DISORDER; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNE DEFICIENCY; LYSOSOME; MACROPHAGE; NATURAL KILLER CELL; NONHUMAN; PRIMARY IMMUNE DEFICIENCY DISORDER; PROGNOSIS; REVIEW; T LYMPHOCYTE; GENETICS; LYMPHOCYTE; PHYSIOLOGY;

HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; LYMPHOCYTES; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MACROPHAGES;

EID: 84907549906     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.09.008     Document Type: Review

References (68)

1. Favara B.E., Feller A.C., Pauli M., Jaffe E.S., Weiss L.M., Arico M., Bucsky P., Egeler R.M., Elinder G., Gadner H., Gresik M., Henter J.I., Imashuku S., Janka-Schaub G., Jaffe R., Ladisch S., Nezelof C., Pritchard J. Contemporary classification of histiocytic disorders. The WHO committee on histiocytic/reticulum cell proliferations. Reclassification Working Group of the Histiocyte Society. Med. Pediatr. Oncol. 1997, 29(3):157-166.
2. Xu X.J., Tang Y.M., Song H., Yang S.L., Xu W.Q., Zhao N., Shi S.W., Shen H.P., Mao J.Q., Zhang L.Y., Pan B.H. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J. Pediatr. 2012, 10.1016/j.jpeds.2011.11.046.
3. Chandrakasan S., Filipovich A.H. Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment. J. Pediatr. Nov 2013, 163(5):1253-1259.
4. Henter J.I., Elinder G., Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin. Oncol. 1991, 18(1):29-33.
5. Writing Group of the Histiocyte Society Histiocytosis syndromes in children. Lancet 1987, 1(8526):208-209.
6. Henter J.I., Samuelsson-Horne A., Aricò M., Egeler R.M., Elinder G., Filipovich A.H., Gadner H., Imashuku S., Komp D., Ladisch S., Webb D., Janka G. Histiocyte Society. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 2002, 100(7):2367-2373.
7. Henter J.I., Horne A., Aricó M., Egeler R.M., Filipovich A.H., Imashuku S., Ladisch S., McClain K., Webb D., Winiarski J., Janka G. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 2007, 48(2):124-131.
8. Janka G.E. Familial hemophagocytic lymphohistiocytosis. Eur. J. Pediatr. 1983, 140(3):221-230.
9. Stepp S.E., Dufourcq-Lagelouse R., Le Deist F., Bhawan S., Certain S., Mathew P.A., Henter J.I., Bennett M., Fischer A., de Saint Basile G., Kumar V. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999, 286(5446):1957-1959.
10. Feldmann J., Callebaut I., Raposo G., Certain S., Bacq D., Dumont C., Lambert N., Ouachée-Chardin M., Chedeville G., Tamary H., Minard-Colin V., Vilmer E., Blanche S., Le Deist F., Fischer A., de Saint Basile G. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 2003, 115:461-473.
11. zur Stadt U., Schmidt S., Kasper B., Beutel K., Diler A.S., Henter J.I., Kabisch H., Schneppenheim R., Nürnberg P., Janka G., Hennies H.C. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum. Mol. Genet. 2005, 14(6):827-834.
12. zur Stadt U., Rohr J., Seifert W., Koch F., Grieve S., Pagel J., Strauss J., Kasper B., Nürnberg G., Becker C., Maul-Pavicic A., Beutel K., Janka G., Griffiths G., Ehl S., Hennies H.C. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. Am. J. Hum. Genet. 2009, 10.1016/j.ajhg.2009.09.005.
13. Ohadi M., Lalloz M.R., Sham P., Zhao J., Dearlove A.M., Shiach C., Kinsey S., Rhodes M., Layton D.M. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping. Am. J. Hum. Genet. 1999, 64(1):165-171.
14. Dotta L., Parolini S., Prandini A., Tabellini G., Antolini M., Kingsmore S.F., Badolato R. Clinical, laboratory and molecular signs of immunodeficiency in patients with partial oculo-cutaneous albinism. Orphanet J. Rare Dis. 2013, 10.1186/1750-1172-8-168.
15. Nagle D.L., Karim M.A., Woolf E.A., Holmgren L., Bork P., Misumi D.J., McGrail S.H., Dussault B.J., Perou C.M., Boissy R.E., Duyk G.M., Spritz R.A., Moore K.J. Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. Nat. Genet. 1996, 10.1038/ng1196-307.
16. Blume R.S., Wolff S.M. The Chediak-Higashi syndrome: studies in four patients and a review of the literature. Medicine (Baltimore) 1972, 51(4):247-280.
17. Introne W., Boissy R.E., Gahl W.A. Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome. Mol. Genet. Metab. 1999, 68(2):283-303.
18. Nagai K., Ochi F., Terui K., Maeda M., Ohga S., Kanegane H., Kitoh T., Kogawa K., Suzuki N., Ohta S., Ishida Y., Okamura T., Wakiguchi H., Yasukawa M., Ishii E. Clinical characteristics and outcomes of Chédiak-Higashi syndrome: a nationwide survey of Japan. Pediatr. Blood Cancer 2013, 10.1002/pbc.24637.
19. Kurugöl Z., Ozkinay F., Vardar F., Karaçali S., Kutukçuler N., Deveci R., Ozkinay C. Griscelli syndrome: report of a case and review of the literature. Pediatr. Int. 2001, 43(3):298-301.
20. Menasche G., Pastural E., Feldmann J., Certain S., Ersoy F., Dupuis S., Wulffraat N., Bianchi D., Fischer A., Le Deist F., de Saint B.G. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat. Genet. 2000, 10.1038/76024.
21. Huizing M., Scher C.D., Strovel E., Fitzpatrick D.L., Hartnell L.M., Anikster Y., Gahi W.A. Nonsense mutations in ADTB3A cause complete deficiency of the {beta}3a subunit of adaptor complex-3 and severe Hermansky-Pudlak syndrome type 2. Pediatr. Res. 2002, 10.1203/00006450-200202000-00006.
22. Dell'Angelica E.C., Shotelersuk V., Aguilar R.C., Gahl W.A., Bonifacino J.S. Altered trafficking of lysosomal proteins in Hermansky-Pudlak syndrome due to mutations in the beta 3A subunit of the AP-3 adaptor. Mol. Cell 1999, 10.1016/S1097-2765(00)80170-7.
23. Fontana S., Parolini S., Vermi W., Booth S., Gallo F., Donini M., Benassi M., Gentili F., Ferrari D., Notarangelo L.D., Cavadini P., Marcenaro E., Dusi S., Cassatella M., Facchetti F., Griffiths G.M., Moretta A., Notarangelo L.D., Badolato R. Innate immunity defects in Hermansky-Pudlak type 2 syndrome. Blood 2006, 10.1182/blood-2005-11-4398.
24. Clark R., Stinchcombe J.C., Day A., Blott E., Booth S., Bossi G. Adaptor protein 3-dependent microtubule-mediated movement of lytic granules to the immunological synapse. Nat. Immunol. 2003, 10.1038/ni1000.
25. Horwitz M.S., Duan Z., Korkmaz B., Lee H.H., Mealiffe M.E., Salipante S.J. Neutrophil elastase in cyclic and severe congenital neutropenia. Blood 2007, 10.1182/blood-2006-08-019166.
26. Sugita M., Cao X., Watts G.F., Rogers R.A., Bonifacino J.S., Brenner M.B. Failure of trafficking and antigen presentation by CD1 in AP-3-deficient cells. Immunity 2002, 10.1016/S1074-7613(02)00311-4.
27. Caplan S., Dell'Angelica E.C., Gahl W.A., Bonifacino J.S. Trafficking of major histocompatibility complex class II molecules in human B-lymphoblasts deficient in the AP-3 adaptor complex. Immunol. Lett. 2000, 10.1016/S0165-2478(00)00176-0.
28. Enders A., Zieger B., Schwarz K., Yoshimi A., Speckmann C., Knoepfle E.M., Kontny U., Müller C., Nurden A., Rohr J., Henschen M., Pannicke U., Niemeyer C., Nurden P., Ehl S. Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood 2006, 10.1182/blood-2005-11-4413.
29. Jessen B., Bode S.F., Ammann S., Chakravorty S., Davies G., Diestelhorst J., Frei-Jones M., Gahl W.A., Gochuico B.R., Griese M., Griffiths G., Janka G., Klein C., Kögl T., Kurnik K., Lehmberg K., Maul-Pavicic A., Mumford A.D., Pace D., Parvaneh N., Rezaei N., de Saint Basile G., Schmitt-Graeff A., Schwarz K., Karasu G.T., Zieger B., Zur Stadt U., Aichele P., Ehl S. The risk of hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type 2. Blood 2013, 10.1182/blood-2012-10-463166.
30. Arico M., Imashuku S., Clementi R., Hibi S., Teramura T., Danesino C., Haber D.A., Nichols K.E. Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene. Blood 2001, 97(4):1131-1133.
31. Sayos J., Wu C., Morra M., Wang N., Zhang X., Allen D., van Schaik S., Notarangelo L., Geha R., Roncarolo M.G., Oettgen H., De Vries J.E., Aversa G., Terhorst C. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 1998, 395(6701):462-469.
32. Coffey A.J., Brooksbank R.A., Brandau O., Oohashi T., Howell G.R., Bye J.M., Cahn A.P., Durham J., Heath P., Wray P., Pavitt R., Wilkinson J., Leversha M., Huckle E., Shaw-Smith C.J., Dunham A., Rhodes S., Schuster V., Porta G., Yin L., Serafini P., Sylla B., Zollo M., Franco B., Bolino A., Seri M., Lanyi A., Davis J.R., Webster D., Harris A., Lenoir G., de St Basile G., Jones A., Behloradsky B.H., Achatz H., Murken J., Fassler R., Sumegi J., Romeo G., Vaudin M., Ross M.T., Meindl A., Bentley D.R. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat. Genet. 1998, 20(2):129-135.
33. Rigaud S., Fondanèche M.C., Lambert N., Pasquier B., Mateo V., Soulas P., Galicier L., Le Deist F., Rieux-Laucat F., Revy P., Fischer A., de Saint Basile G., Latour S. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 2006, 444(7115):110-114.
34. Pachlopnik Schmid J., Canioni D., Moshous D., Touzot F., Mahlaoui N., Hauck F., Kanegane H., Lopez-Granados E., Mejstrikova E., Pellier I., Galicier L., Galambrun C., Barlogis V., Bordigoni P., Fourmaintraux A., Hamidou M., Dabadie A., Le Deist F., Haerynck F., Ouachée-Chardin M., Rohrlich P., Stephan J.L., Lenoir C., Rigaud S., Lambert N., Milili M., Schiff C., Chapel H., Picard C., de Saint Basile G., Blanche S., Fischer A., Latour S. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 2011, 10.1182/blood-2010-07-298372.
35. Huck K., Feyen O., Niehues T., Rüschendorf F., Hübner N., Laws H.J., Telieps T., Knapp S., Wacker H.H., Meindl A., Jumaa H., Borkhardt A. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J. Clin. Invest. 2009, 119(5):1350-1358.
36. Felices M., Berg L.J. The Tec kinases Itk and Rlk regulate NKT cell maturation, cytokine production, and survival. J. Immunol. 2008, 180(5):3007-3018.
37. Readinger J.A., Mueller K.L., Venegas A.M., Horai R., Schwartzberg P.L. Tec kinases regulate T-lymphocyte development and function: new insights into the roles of Itk and Rlk/Txk. Immunol. Rev. 2009, 228(1):93-114.
38. Stepensky P., Weintraub M., Yanir A., Revel-Vilk S., Krux F., Huck K., Linka R.M., Shaag A., Elpeleg O., Borkhardt A., Resnick I.B. IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach. Haematologica 2011, 10.3324/haematol.2010.033910.
39. Chiossone L., Chaix J., Fuseri N., Roth C., Vivier E., Walzer T. Maturation of mouse NK cells is a 4-stage developmental program. Blood 2009, 113(22):5488-5496.
40. Hamann D., Baars P.A., Rep M.H., Hooibrink B., Kerkhof-Garde S.R., Klein M.R., van Lier R.A. Phenotypic and functional separation of memory and effector human CD8+ T cells. J. Exp. Med. 1997, 186(9):1407-1418.
41. Klein U., Rajewsky K., Kuppers R. Human immunoglobulin (Ig)M+IgD+peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J. Exp. Med. 1998, 188(9):1679-1689.
42. Salzer E., Daschkey S., Choo S., Gombert M., Santos-Valente E., Ginzel S., Schwendinger M., Haas O.A., Fritsch G., Pickl W.F., Förster-Waldl E., Borkhardt A., Boztug K., Bienemann K., Seidel M.G. Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27. Haematologica 2013, 10.3324/haematol.2012.068791.
43. Voss S.D., Hong R., Sondel P.M. Severe combined immunodeficiency, interleukin-2 (IL-2), and the IL-2 receptor: experiments of nature continue to point the way. Blood 1994, 83(3):626-635.
44. Grunebaum E., Zhang J., Dadi H., Roifman C.M. Haemophagocytic lymphohistiocytosis in X-linked severe combined immunodeficiency. Br. J. Haematol. 2000, 108(4):834-837.
45. Suzuki N., Morimoto A., Ohga S., Kudo K., Ishida Y., Ishii E. HLH/LCH committee of the Japanese Society of Pediatric Hematology. Characteristics of hemophagocytic lymphohistiocytosis in neonates: a nationwide survey in Japan. J. Pediatr. Aug 2009, 155(2):235-238.e1.
46. Grunebaum E., Cohen A., Roifman C.M. Recent advances in understanding and managing adenosine deaminase and purine nucleoside phosphorylase deficiencies. Curr. Opin. Allergy Clin. Immunol. 2013, 10.1097/ACI.0000000000000006.
47. Wakefield R., McClean P., Gooi H.C., Batcup G., Richards M. Fatal haemophagocytic lymphohistiocytosis (HLH) associated with measles infection and purine nucleoside phosphorylase deficiency. Br. J. Haematol. 2001, 113(Supp. 1):43.
48. Davies E.G. Immunodeficiency in DiGeorge syndrome and options for treating cases with complete athymia. Front. Immunol. 2013, 4:322.
49. Aricò M., Bettinelli A., Maccario R., Clementi R., Bossi G., Danesino C. Hemophagocytic lymphohistiocytosis in a patient with deletion of 22q11.2. Am. J. Med. Genet. 1999, 87(4):329-330.
50. Cesaro S., Messina C., Sainati L., Danesino C., Aricò M. Del 22Q11.2 and hemophagocytic lymphohistiocytosis: a non-random association. Am. J. Med. Genet. A 2003, 116A(2):208-209.
51. Touraine R.L., Pondarre C., Till M., Bertrand Y. Hemophagocytic lymphohistiocytosis and del 22q11 [abstract]. Genet. Couns. 1999, 10:114-115.
52. Buchbinder D., Nugent D.J., Fillipovich A.H. Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments. Appl. Clin. Genet. 2014, 7:55-66.
53. Matalon O., Reicher B., Barda-Saad M. Wiskott-Aldrich syndrome protein-dynamic regulation of actin homeostasis: from activation through function and signal termination in T lymphocytes. Immunol. Rev. 2013, 10.1111/imr.12112.
54. Pasic S., Micic D., Kuzmanovic M. Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis in Wiskott-Aldrich syndrome. Acta Paediatr. 2003, 92(7):859-861.
55. Plantinga T.S., Johnson M.D., Scott W.K., Joosten L.A., van der Meer J.W., Perfect J.R., Kullberg B.J., Netea M.G. Human genetic susceptibility to Candida infections. Med. Mycol. 2012, 10.3109/13693786.2012.690902.
56. van de Veerdonk F.L., Plantinga T.S., Hoischen A., Smeekens S.P., Joosten L.A., Gilissen C., Arts P., Rosentul D.C., Carmichael A.J., der Graaf CA Smits-van, Kullberg B.J., van der Meer J.W., Lilic D., Veltman J.A., Netea M.G. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N. Engl. J. Med. 2011, 10.1056/NEJMoa1100102.
57. Takezaki S., Yamada M., Kato M., Park M.J., Maruyama K., Yamazaki Y., Chida N., Ohara O., Kobayashi I., Ariga T. Chronic mucocutaneous candidiasis caused by a gain-of-function mutation in the STAT1 DNA-binding domain. J. Immunol. 2012, 10.4049/jimmunol.1200926.
58. Faitelson Y., Bates A., Shroff M., Grunebaum E., Roifman C.M., Naqvi A. A mutation in the STAT1 DNA-binding domain associated with hemophagocytic lymphohistocytosis. Lympho Sign June 24 2014, 1-9.
59. Roos D., de Boer M. Molecular diagnosis of chronic granulomatous disease. Clin. Exp. Immunol. 2014, 10.1111/cei.12202.
60. Parekh C., Hofstra T., Church J.A., Coates T.D. Hemophagocytic lymphohistiocytosis in children with chronic granulomatous disease. Pediatr. Blood Cancer 2011, 10.1002/pbc.22830.
61. Maas A., Hendriks R.W. Role of Bruton's tyrosine kinase in B cell development. Dev. Immunol. 2001, 8(3-4):171-181.
62. Schultz K.A., Neglia J.P., Smith A.R., Ochs H.D., Torgerson T.R., Kumar A. Familial hemophagocytic lymphohistiocytosis in two brothers with X-linked agammaglobulinemia. Pediatr. Blood Cancer 2008, 10.1002/pbc.21573.
63. Lougaris V., Baronio M., Vitali M., Tampella G., Cattalini M., Tassone L., Soresina A., Badolato R., Plebani A. Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation. J. Allergy Clin. Immunol. 2014, 10.1016/j.jaci.2013.12.1085.
64. López-Herrera G., Vargas-Hernández A., González-Serrano M.E., Berrón-Ruiz L., Rodríguez-Alba J.C., Espinosa-Rosales F., Santos-Argumedo L. Bruton's tyrosine kinase-an integral protein of B cell development that also has an essential role in the innate immune system. J. Leukoc. Biol. 2014, 10.1189/jlb.0513307.
65. Bhatia S., Bauer F., Bilgrami S.A. Candidiasis-associated hemophagocytic lymphohistiocytosis in a patient infected with human immunodeficiency virus. Clin. Infect. Dis. Dec 1 2003, 37(11):e161-e166.
66. Frederiksen J.K., Ross C.W. Cytomegalovirus-associated hemophagocytic lymphohistiocytosis in a patient with myasthenia gravis treated with azathioprine. Blood 2014, 123(15):2290.
67. Villa A., Notarangelo L.D., Roifman C.M. Omenn syndrome: inflammation in leaky severe combined immunodeficiency. J. Allergy Clin. Immunol. 2008, 122(6):1082-1086.
68. Lykens J.E., Terrell C.E., Zoller E.E., Risma K., Jordan M.B. Perforin is a critical physiologic regulator of T-cell activation. Blood Jul 21 2011, 118(3):618-626.